#	Pagina
attuale pagina	/open-h2020/projects/205155/index.html

Opendata, web and dolomites

tagMDR

Identification of Multidrug Resistance for Chemotherapy Guidance in Cancer Using a Lab-on-a-chip Platform

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

tagMDR project word cloud

Explore the words cloud of the tagMDR project. It provides you a very rough idea of what is the project "tagMDR" about.

depends diagnostic discrimination vitro avoiding quantification despite picking cheaper medical points markets cancer therapy identification feasibility diseases ages accurate collaborators cells sterilization mdr agents structures positioning happier first diagnosis resistant clinical tests lethal predictable resistance isolation marketing initial microfluidics business elaborated chemotherapy progression inappropriate harmful guide free multidrug certifications successful metastatic treatments outcome plan rapid device ce market chemotherapeutic deleterious framework tagmdr operate label prior people meantime shorter ivd manner structuring suitable ide worldwide oncologists strategy types innovation selling treatment customers hence yielding course prevalent

Project "tagMDR" data sheet

The following table provides information about the project.

Coordinator	MIKRO BIYOSISTEMLER ELEKTRONIK SANAYI VE TICARET ANONIM SIRKETI Organization address address: MUSTAFA KEMAL MAH DUMLUPINAR BLV ODTU TEKNOKENT ME YERLESKESI NO 280 B BLOK OFIS 10 city: CANKAYA ANKARA postcode: 6530 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Turkey [TR]
Project website	http://mikrobiyo.com.tr/product/ctc-detection-systems
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SMEINST-1-2016-2017
Funding Scheme	SME-1
Starting year	2016
Duration (year-month-day)	from 2016-08-01 to 2016-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	MIKRO BIYOSISTEMLER ELEKTRONIK SANAYI VE TICARET ANONIM SIRKETI MIKRO BIYOSISTEMLER ELEKTRONIK SANAYI VE TICARET ANONIM SIRKETI Organization address address: MUSTAFA KEMAL MAH DUMLUPINAR BLV ODTU TEKNOKENT ME YERLESKESI NO 280 B BLOK OFIS 10 city: CANKAYA ANKARA postcode: 6530 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	TR (CANKAYA ANKARA)	coordinator	50˙000.00

Map

Project objective

Cancer is one of the most lethal and prevalent diseases affecting people from all ages worldwide. Despite its harmful side effects, chemotherapy is still the main course of treatment in most of the cancer types, and the success of the therapy highly depends on the early diagnosis, i.e. before metastatic progression. One of the major factors affecting the success of chemotherapy is the development of multidrug resistance (MDR), where the cancer cells become resistant to chemotherapeutic agents with distinct structures.

The objective of this innovation project is to develop the first clinical device (tagMDR) for the identification of MDR prior to or during cancer treatment. Being a low cost and easy-to-operate in vitro diagnostic (IVD) device, tagMDR will provide rapid and accurate discrimination and quantification of resistant cancer cells via a label-free and target specific isolation technology. This novel system will guide the medical oncologists for picking the most effective treatment strategy in a timely manner, avoiding the deleterious side effects of inappropriate chemotherapy and the associated costs. The unique selling points of tagMDR will be the cheaper, shorter, more predictable, and more successful chemotherapy treatments, and hence yielding happier people.

An initial market study has already been carried out for determining the potential customers and partners for structuring the general framework of the business plan. This study will be detailed in Phase 1, and the potential collaborators for clinical tests and marketing will be investigated, following the market potential assessment and the cost analysis of tagMDR. Meantime, the procedures for CE and IDE certifications and the suitable sterilization methods will also be identified. The major outcome of the feasibility study will be an elaborated business plan for the next 10 years, to enable accurate positioning of tagMDR in IVD and microfluidics markets.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TAGMDR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TAGMDR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

ESCALON (2019)

European-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer development

RESHAPE (2019)

Reshaping undesired Inflammation in challenged Tissue Homeostasis by Next-Generation regulatory T cell (Treg) Approaches – from Advanced Technology Developments to First-in-Human Trials